Capital Research Global Investors
INBX icon

Capital Research Global Investors’s Inhibrx INBX Stock Holding History

Capital Research Global Investors’s Portfolio INBX Stock Details INBX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$26.4M Sell
392,847
-28,728
-7% -$2.13M ﹤0.01% 399
2025
Q4 		$33.3M Buy
+421,575
New +$28.7M 0.01% 372

Other funds holding INBX

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
S
Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $103B AUM 28.65% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Capital Research Global Investors's INBX Position: Q1 2026 in Review

Capital Research Global Investors reduced its Inhibrx (INBX) stake by 6.8% in Q1 2026, selling an estimated $2.13M and leaving 392,847 shares worth $26.4M. The position accounts for ﹤0.01% of the portfolio, ranked #399.

Capital Research Global Investors first reported a position in INBX in Q4 2025 and has held it in 2 quarters since. The position peaked at $33.3M in Q4 2025. 135 funds tracked by Wall St. Rank hold INBX as of Q1 2026.

  • Capital Research Global Investors held 392,847 shares of Inhibrx worth $26.4M as of Q1 2026.
  • Capital Research Global Investors sold 28,728 Inhibrx shares in Q1 2026, an estimated $2.13M.
  • Inhibrx made up ﹤0.01% of Capital Research Global Investors's portfolio in Q1 2026, its #399 holding.
  • Capital Research Global Investors first reported a position in Inhibrx in Q4 2025 and has held it in 2 quarters since.
  • Capital Research Global Investors's Inhibrx position peaked at $33.3M in Q4 2025.
  • 135 funds tracked by Wall St. Rank held Inhibrx as of Q1 2026.

Based on Capital Research Global Investors's 13F filing for Q1 2026, filed 13 May 2026.